PINPOINT GENE THERAPIES FOR CHRONIC DISEASES

Next generation precision molecular medicines to tackle, in a safe and durable way, chronic diseases at their local root.

See more

Our mission

Providing safe, efficacious, and affordable therapies to patients with severe localized chronic diseases.

How we do it

Unlocking the full potential of non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors as a powerful gene therapy platform. This allows for the expression of large genes under the control of sophisticated regulatory elements, in a safe and redosable manner.

Our technology

We are passionate about making a difference for patients with chronic diseases. We are developing a powerful gene therapy platform, and the critical manufacturing infrastructure, to do this.

We are exploiting the natural properties of the Herpes Simplex Virus 1 (HSV-1) to establish lifelong latency in peripheral neurons in harmony with its human host. This should ensure safe, highly specific, and durable expression of the disease modifying transgene to treat the local roots of severe, chronic diseases. We are designing vectors that we can easily engineer from a smart backbone and efficiently manufacture using our specific cell line in a GMP compliant process.

Our initial focus is peripheral nervous system disorders. We are experts in engineering vectors with specific promoters to achieve relevant targeted effects in a specific neuronal subset of sensory or autonomic nervous system.

We are developing a rich pipeline of vectors targeting different indications. Our most advanced project targets Type C neurons for the treatment of neurogenic bladder disorders, starting with the one affecting patients with spinal cord injuries. 

We are hiring! Help EG 427 Shape the Future of Gene Therapy!

We are actively recruiting. If you’d like to join our talented team to help make a difference for people with chronic diseases then see our Join Us section for open job opportunities.

Learn more  >

Funding and Support

BPI France, France’s Ministry of Research, and the Ile-de-France region have funded the company with multiple non-dilutive loans and grants as part of their work to deliver the French government’s policy of support for French start-ups by fuelling their R&D to accelerate innovation through grants and loans.

×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.